Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 4

Wnt signaling pathway activities may be altered in primary Sjogren’s syndrome

Pages
2015–2022
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, it can be concluded that the Wnt/β-catenin pathway activities may be altered in case of glandular inflammation.Key words: Sjögren syndrome, wingless, sclerostin, dickkopf -1

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Sjögren’s syndrome (SS) is an autoimmune disease and its pathogenesis is still not completely clear.
📊
Key Findings & Data:This study aims to determine the serum and saliva levels of Dickkopf (DKK)1 and sclerostin and to evaluate Wnt-1 and Wnt-3a expression in the salivary gland in patients with primary SS.
💡
Conclusion & Impact:Therefore, it can be concluded that the Wnt/β-catenin pathway activities may be altered in case of glandular inflammation.Key words: Sjögren syndrome, wingless, sclerostin, dickkopf -1
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Sjögren’s syndrome (SS) is an autoimmune disease and its pathogenesis is still not completely clear. The wingless (Wnt)/β-catenin pathway has recently been shown to play an important role in inflammation. This study aims to determine the serum and saliva levels of Dickkopf (DKK)1 and sclerostin and to evaluate Wnt-1 and Wnt-3a expression in the salivary gland in patients with primary SS. Materials and methods: This study included 30 patients diagnosed with SS, 30 patients diagnosed with systemic lupus erythematosus (SLE), and 29 healthy controls. Serum and saliva levels of DKK1 and sclerostin were measured and the expressions of Wnt1 and Wnt3a in the salivary gland were measured immunohistochemically. Results: Serum DKK1 and sclerostin levels were lower in the SS and SLE groups compared to the control group (both p < 0.001). Saliva DKK1 levels were higher in the SS group compared to the control and SLE groups (p = 0.004 and p = 0.009, respectively). Wnt1 and Wnt3a expression were found in salivary gland tissue samples in 71.4% of primary SS patients and relatively frequent than control group. Conclusions: Serum DKK1 and sclerostin levels in primary SS and SLE were decreased. Moreover, levels of Wnt1 and Wnt3a expression in the salivary gland were also elevated in primary SS. Therefore, it can be concluded that the Wnt/β-catenin pathway activities may be altered in case of glandular inflammation.Key words: Sjögren syndrome, wingless, sclerostin, dickkopf -1

🔖

Cite This Article

KOCA, S. S., ÖZ, B., KARATAŞ, A., GÖZEL, N., DAĞLI, A. F., ÖMERCİKOĞLU, Z., ÇATAK, O., ERMAN, F., ŞAHİN, K. (2022). Wnt signaling pathway activities may be altered in primary Sjogren’s syndrome. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 4, 2015–2022. https://ajindex.com/articles/609502

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR. Estimating the prevalence among Caucasian women of primary Sjögren’s syndrome in two general practices in Birmingham, UK. Scandinavian Journal of Rheumatology 2004
  2. 33 (1): 39-43. doi:10.1080/03009740310004676 2. Daniels TE, Fox PC. Salivary and oral components of Sjögren’s syndrome. Rheumatic Disease Clinics of North America 1992
  3. 18 (3): 571-589 3. Kramer JM. Early events in Sjögren’s Syndrome pathogenesis: the importance of innate immunity in disease initiation. Cytokine 2014
  4. 67 (2): 92-101. doi: 10.1016/j.cyto.2014.02.009 4. Cafaro G, Croia C, Argyropoulou OD, Leone MC, Orlandi M et al. One year in review 2019: Sjögren’s syndrome. Clinical and Experimental Rheumatology 2019
  5. 37118 (3): 3-15. 5. Sandhya P, Kurien BT, Danda D, Scofield RH. Update on pathogenesis of Sjogren’s Syndrome. Current Rheumatology Reviews 2017
  6. 13 (1): 5-22. doi: 10.2174/15733971126661607 14164149 6. García-Carrasco M, Fuentes-Alexandro S, Escárcega RO, Salgado G, Riebeling C et al. Pathophysiology of Sjögren’s syndrome. Archives of Medical Research 2006
  7. 37 (8): 921-932. doi: 10.1016/j.arcmed.2006.08.002 7. Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sjögren’s syndrome. Rheumatology (Oxford) 2019
  8. key370. doi: 10.1093/rheumatology/key370 8. Maarse F, Jager DH, Forouzanfar T, Wolff J, Brand HS. Tooth loss in Sjögren’s syndrome patients compared to age and gender matched controls. Medicina Oral Patologia Oral y Cirugia Bucal 2018
  9. 23 (5): e545-e551. doi: 10.4317/medoral.22545 9. Kim SY, Lee J, Choi YS, Kim JW, Kwok SK et al. Do I sound dry? Comparative voice analysis of primary Sjögren’s syndrome. Clinical and Experimental Rheumatology 2018
  10. 112 (3): 130- 136. 10. Brito-Zerón P, Retamozo S, Kostov B, Baldini C, Bootsma H et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome. RMD Open 2019
  11. 5 (2): e001064. doi: 10.1136/ rmdopen-2019-001064 11. Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nature Reviews Immunology 2008
  12. 8 (8): 581-593. doi: 10.1038/nri2360 12. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012
  13. 149 (6): 1192-1205. doi: 10.1016/j.cell.2012.05.012 13. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008
  14. 4 (2): 68-75. doi: 10.4161/org.4.2.5851 14. Tamai K, Semenov M,